Novel Ocular Drug Delivery Devices Market: Focus on Implants, Inserts and Punctal Plugs, 2021-2030

 

There is an evident rise in the demand for effective, non-invasive drug delivery systems that are capable of overcoming bioavailability hurdles and enable delivery of the drug at the target cells, at effective concentrations, for a suitable period of time. In our research, 50 drug delivery devices that have been / are being developed by various industry players across the world.

To order this detailed 180+ page report, please visit this - https://www.rootsanalysis.com/reports/novel-ocular-drug-delivery-devices-market.html

 

 

The novel ocular drug delivery market is highly fragmented, featuring the presence of established, as well as emerging players. Further, majority (75%) of the developers engaged in this domain are based in North America; examples, include (in alphabetical order) Aerie Pharmaceuticals, Alimera Sciences, Amorphex Therapeutics, Bausch and Lomb, EyePoint Pharmaceuticals and Genentech. This is followed by players headquartered in RoW (13%), Asia Pacific (6%) and Europe (6%).

To Request for sample - https://www.rootsanalysis.com/reports/novel-ocular-drug-delivery-devices-market/request-sample.html

 

Implants (80%) emerged as the most common type of combination device being developed by stakeholders engaged in this domain. As is evident from the figure, 43% candidates are being evaluated across different clinical phases, of which, 23% are in phase II trials and 15% are in phase I studies. topical emerged as the most popular (40%) route of administration, followed by intravitreal route (35%), adopted by novel ocular drug delivery devices. It is worth mentioning that topical route primarily targets the anterior eye diseases, while the intravitreal route is widely used for the treatment of posterior eye diseases.[1]

 

 

Majority (88 %) of the combinational devices are being developed for delivery of small molecules, followed by biologic (12%). It is worth mentioning that, of these, 60% are biodegradable, followed by 40% of non-biodegradable devices. It is worth mentioning that biodegradable implants contain natural and synthetic polymers which can help in achieving controlled release of formulation for longer duration.[2] Further, maximum number of combinational devices products are being developed for treatment of glaucoma (17); Examples include (in alphabetical order) Latanoprost (Mati Therapeutics), Durysta (Allergan), ENV515 (Aerie Pharmaceuticals), EXP-LP (Eximore), Glaucoma Implant (Polyactiva) and Glaucoma Implant (Polyactiva) Latanoprost (Mati Therapeutics). route primarily targets the anterior eye diseases, while the intravitreal route is widely used for the treatment of posterior eye diseases.[3]

 

You may also be interested in the following titles:

1.     Peptides and Macrocycle Drug Discovery: Services and Platforms Market, 2020 - 2030

2.     China Biopharmaceutical Contract Manufacturing Market, 2020-2030

3.     Antibody Contract Manufacturing Market, 2020 - 2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Details

Ben Johnson

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

 

Roots Analysis

Web: https://www.rootsanalysis.com/

LinkedIn: https://in.linkedin.com/company/roots-analysis

Twitter: https://twitter.com/RootsAnalysis.com

Medium: https://medium.com/@RootsAnalysis

Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/

Quora: https://rootsanalysisinsights.quora.com/

 

 

 

Comments

Post a Comment

Popular posts from this blog

The microbial contract biomanufacturing market is growing at a CAGR of 8.7%, claims {Roots Analysis}

    The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragments and plasmid-based therapies, is anticipated to offer lucrative opportunities to service providers serving this niche, but growing market segment     London   Roots Analysis has announced the addition of the “ Microbial Contract Biomanufacturing Market, 2020-2030 ” report to its list of offerings.   Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly. Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics. Given the obvious advantages of outsourcing, drug developers are likely to continue relying on contract service providers for various...
Read more

Manufacturing Market Continuous (Small Molecules and Biologics), 2020 – 2030 by Roots Analysis

  Recent advances in the manufacturing technologies have prompted pharmaceutical companies to consider shifting from the traditional multi-step, batch manufacturing processes to faster, and relatively more efficient continuous manufacturing   Roots Analysis is pleased to announce the publication of its recent study, titled, “ Manufacturing Market Continuous (Small Molecules and Biologics), 2020 – 2030 .”   The report features an extensive study of the current market landscape and future opportunities for companies with capabilities in continuous manufacturing (both innovator companies with in-house expertise and contract manufacturers). It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: §   A detailed assessment of the overall landscape of companies with capabilities for continuous manufacturing §   Elaborate profiles of some of the key...
Read more

A relatively larger proportion of these firms are headquartered in the US, claims Roots Analysis

  Lately, drug manufacturers have started showing evident interest in modular facilities and using modularity in design approaches owing to the amplified value of smaller production facilities, which are more efficient and flexible. The increased demand for multi-product, multi-purpose, smaller batch size facilities has also prompted equipment manufacturers to revisit their product offerings.   To order this 300+ page report, which features 120+ figures and 130+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/modular-facilities-flexible-drug-manufacturing-platforms-of-the-future/178.html   The USD xx billion (by 2030) financial opportunity within the modular facilities market has been analyzed across the following segments: ·        Type of Modular Construct  §   Hybrid Skid §   Plug-and-Play §   Skid-Mounted §   Truckable §   Others §   Type of Construc...
Read more